Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Int J Mol Sci. 2021 Sep 26;22(19):10381. doi: 10.3390/ijms221910381.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients' lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.
特应性皮炎（AD）是最常见的慢性炎症性皮肤病，严重影响患者的生活，尤其是在严重的情况下。AD 的临床表现随疾病进程、不同年龄组和种族而变化。AD 的特征是一系列临床表型和内型。本文从当前 AD 发病机制的描述入手，探讨了从保湿剂到生物制剂的已批准 AD 治疗方法的合理性，并介绍了一些新的有前途的药物。
